Definium Therapeutics Target of Unusually Large Options Trading (NASDAQ:DFTX)

Definium Therapeutics, Inc. (NASDAQ:DFTX) was the recipient of some unusual options trading activity on Friday. Investors purchased 8,130 call options on the company. This is an increase of 460% compared to the average volume of 1,451 call options.

Wall Street Analyst Weigh In

A number of brokerages recently commented on DFTX. Leerink Partners lifted their price objective on Definium Therapeutics from $23.00 to $30.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 22nd. Piper Sandler reissued an “overweight” rating and issued a $48.00 target price (down from $49.00) on shares of Definium Therapeutics in a research note on Friday, May 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Definium Therapeutics in a report on Tuesday, April 21st. Wolfe Research assumed coverage on Definium Therapeutics in a research report on Monday, February 23rd. They set an “outperform” rating and a $25.00 target price for the company. Finally, HC Wainwright upped their price target on Definium Therapeutics from $55.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $37.92.

Definium Therapeutics Trading Up 2.7%

Definium Therapeutics stock traded up $0.64 during mid-day trading on Friday, hitting $24.75. 1,727,239 shares of the company’s stock were exchanged, compared to its average volume of 2,076,640. The company’s 50 day simple moving average is $22.32 and its 200-day simple moving average is $17.93. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $2.47 billion, a P/E ratio of -9.94 and a beta of 2.37. Definium Therapeutics has a fifty-two week low of $6.34 and a fifty-two week high of $26.25.

Definium Therapeutics (NASDAQ:DFTX) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.23). On average, equities analysts anticipate that Definium Therapeutics will post -2.3 earnings per share for the current year.

Institutional Trading of Definium Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. BIT Capital GmbH acquired a new position in shares of Definium Therapeutics during the third quarter worth about $26,000. Fifth Third Bancorp raised its position in Definium Therapeutics by 5,593.2% in the 3rd quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock valued at $40,000 after buying an additional 3,300 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in Definium Therapeutics by 110.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after acquiring an additional 2,003 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in Definium Therapeutics by 56.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock valued at $55,000 after acquiring an additional 3,020 shares in the last quarter. Finally, Flagship Harbor Advisors LLC acquired a new position in Definium Therapeutics during the 4th quarter worth approximately $117,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.